QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
OTCMKTS:MRMD

MariMed (MRMD) Stock Forecast, Price & News

$0.41
-0.01 (-1.22%)
(As of 05:34 PM ET)
Compare
Today's Range
$0.40
$0.44
50-Day Range
$0.37
$0.52
52-Week Range
$0.28
$0.77
Volume
157,169 shs
Average Volume
256,968 shs
Market Capitalization
$140.99 million
P/E Ratio
20.26
Dividend Yield
N/A
Price Target
$0.85

MariMed MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
107.3% Upside
$0.85 Price Target
Short Interest
Healthy
0.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars


MRMD stock logo

About MariMed (OTCMKTS:MRMD) Stock

MariMed, Inc. engages in direct owning of cannabis licenses and management of seed-to-sale operations. It focuses on the development, operation, management, and optimization of facilities for the cultivation, production, and dispensing of medicinal and recreational cannabis and cannabis-infused products. The company was founded by Robert N. Fireman and Jon Levine on January 25, 2011 and is headquartered in Norwood, MA.

Receive MRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter.

MRMD Stock News Headlines

MariMed (OTC: MRMD)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
MariMed Reports First Quarter 2023 Earnings
Contrasting MariMed (OTCMKTS:MRMD) and Mannatech (NASDAQ:MTEX)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
MariMed Inc. (OTCMKTS:MRMD) Short Interest Update
MariMed Announces First Quarter 2023 Earnings Date
MariMed Stock (OTC:MRMD), Dividends
MariMed Announces Fourth Quarter 2022 Earnings Date
MariMed Inc. (OTC:MRMD) Q3 2022 Earnings Call Transcript
See More Headlines
Receive MRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter.

MRMD Company Calendar

Last Earnings
11/15/2021
Today
5/31/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:MRMD
Fax
N/A
Employees
260
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$0.85
High Stock Price Forecast
$0.85
Low Stock Price Forecast
$0.85
Forecasted Upside/Downside
+107.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$13.47 million
Pretax Margin
9.80%

Debt

Sales & Book Value

Annual Sales
$134.01 million
Cash Flow
$0.06 per share
Book Value
$0.19 per share

Miscellaneous

Free Float
266,874,000
Market Cap
$142.73 million
Optionable
Not Optionable
Beta
3.02

Key Executives

  • Jon R. Levine
    President, CEO, Secretary, Treasurer & Director
  • Timothy Shaw
    Chief Operating Officer
  • Susan M. Villare
    Chief Financial Officer
  • Jay O’Malley
    Vice President-Marketing & Research & Development
  • Ryan Crandall
    Chief Revenue Officer













MRMD Stock - Frequently Asked Questions

Should I buy or sell MariMed stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MariMed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRMD shares.
View MRMD analyst ratings
or view top-rated stocks.

What is MariMed's stock price forecast for 2023?

1 brokerages have issued 1-year price targets for MariMed's shares. Their MRMD share price forecasts range from $0.85 to $0.85. On average, they anticipate the company's stock price to reach $0.85 in the next twelve months. This suggests a possible upside of 107.3% from the stock's current price.
View analysts price targets for MRMD
or view top-rated stocks among Wall Street analysts.

How have MRMD shares performed in 2023?

MariMed's stock was trading at $0.3562 on January 1st, 2023. Since then, MRMD shares have increased by 15.1% and is now trading at $0.41.
View the best growth stocks for 2023 here
.

Are investors shorting MariMed?

MariMed saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 16,000 shares, an increase of 100.0% from the April 15th total of 8,000 shares. Based on an average daily volume of 512,100 shares, the days-to-cover ratio is presently 0.0 days.
View MariMed's Short Interest
.

How were MariMed's earnings last quarter?

MariMed Inc. (OTCMKTS:MRMD) announced its quarterly earnings results on Monday, November, 15th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $33.21 million for the quarter. MariMed had a trailing twelve-month return on equity of 17.80% and a net margin of 6.30%.

What guidance has MariMed issued on next quarter's earnings?

MariMed updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $150.00M-, compared to the consensus revenue estimate of $149.65 million.

What other stocks do shareholders of MariMed own?
What is MariMed's stock symbol?

MariMed trades on the OTCMKTS under the ticker symbol "MRMD."

How do I buy shares of MariMed?

Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MariMed's stock price today?

One share of MRMD stock can currently be purchased for approximately $0.41.

How much money does MariMed make?

MariMed (OTCMKTS:MRMD) has a market capitalization of $142.73 million and generates $134.01 million in revenue each year. The company earns $13.47 million in net income (profit) each year or $0.02 on an earnings per share basis.

How many employees does MariMed have?

The company employs 260 workers across the globe.

How can I contact MariMed?

MariMed's mailing address is 11 ROYAL ROAD, BROOKLINE MA, 02445. The official website for the company is marimedadvisors.com. The company can be reached via phone at (617) 795-5140 or via email at ir@mattio.com.

This page (OTCMKTS:MRMD) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -